Andrej Lissat

1.1k total citations
17 papers, 181 citations indexed

About

Andrej Lissat is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Andrej Lissat has authored 17 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Andrej Lissat's work include Neuroblastoma Research and Treatments (5 papers), Glioma Diagnosis and Treatment (4 papers) and Protein Degradation and Inhibitors (4 papers). Andrej Lissat is often cited by papers focused on Neuroblastoma Research and Treatments (5 papers), Glioma Diagnosis and Treatment (4 papers) and Protein Degradation and Inhibitors (4 papers). Andrej Lissat collaborates with scholars based in Germany, United States and Canada. Andrej Lissat's co-authors include Udo Kontny, Charlotte M. Niemeyer, Stefan Kubicek, Uwe Rix, Alexey Stukalov, Jacques Colinge, Georg Winter, Sebastian Nijman, Heinrich Kovar and Giulio Superti‐Furga and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Andrej Lissat

17 papers receiving 180 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrej Lissat Germany 7 94 55 43 31 26 17 181
E. L. Woodward Sweden 8 113 1.2× 20 0.4× 50 1.2× 25 0.8× 15 0.6× 14 225
Luca Paruzzo Italy 6 71 0.8× 33 0.6× 99 2.3× 58 1.9× 9 0.3× 12 192
Shyamprasad Deraje Vasudeva United States 5 142 1.5× 66 1.2× 73 1.7× 38 1.2× 9 0.3× 8 229
L. Nolan United Kingdom 6 100 1.1× 23 0.4× 112 2.6× 38 1.2× 24 0.9× 13 244
Manuel Torres-Diz Spain 6 158 1.7× 32 0.6× 75 1.7× 37 1.2× 9 0.3× 11 218
Fenglin Zang China 10 92 1.0× 45 0.8× 71 1.7× 33 1.1× 12 0.5× 22 211
J A P Spijkers-Hagelstein Netherlands 7 150 1.6× 25 0.5× 55 1.3× 26 0.8× 12 0.5× 9 293
Candace Shelton United States 5 136 1.4× 35 0.6× 36 0.8× 44 1.4× 6 0.2× 5 161
Andrea Garofalo United States 8 92 1.0× 47 0.9× 52 1.2× 45 1.5× 4 0.2× 22 192
Hengyu Lu United States 8 158 1.7× 55 1.0× 111 2.6× 29 0.9× 10 0.4× 11 269

Countries citing papers authored by Andrej Lissat

Since Specialization
Citations

This map shows the geographic impact of Andrej Lissat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrej Lissat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrej Lissat more than expected).

Fields of papers citing papers by Andrej Lissat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrej Lissat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrej Lissat. The network helps show where Andrej Lissat may publish in the future.

Co-authorship network of co-authors of Andrej Lissat

This figure shows the co-authorship network connecting the top 25 collaborators of Andrej Lissat. A scholar is included among the top collaborators of Andrej Lissat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrej Lissat. Andrej Lissat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Steffen, Ingo G., Christiane Chen‐Santel, Andrej Lissat, et al.. (2024). Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study. Leukemia. 39(2). 337–345. 1 indexed citations
2.
3.
Lissat, Andrej, Ingo G. Steffen, Jean‐Pierre Bourquin, et al.. (2021). Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma—A Report from the ALL-REZ Study Group. Journal of Clinical Medicine. 10(22). 5292–5292. 3 indexed citations
4.
Lissat, Andrej, A von Stackelberg, Nadine Thieme, et al.. (2019). Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature. Therapeutic Advances in Medical Oncology. 11. 3862493053–3862493053. 7 indexed citations
5.
Lindner, Sven, Yi Bei, Heathcliff Dorado García, et al.. (2019). Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Cancer Letters. 445. 24–33. 20 indexed citations
6.
Ziegler, David S., François Doz, Birgit Geoerger, et al.. (2019). Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours. Annals of Oncology. 30. ix124–ix124. 5 indexed citations
7.
Doz, François, Birgit Geoerger, Steven G. DuBois, et al.. (2019). RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology. 21(Supplement_6). vi231–vi231. 3 indexed citations
8.
Hargrave, Darren, Lucas Moreno, Alberto Broniscer, et al.. (2018). Dabrafenib in pediatric patients with BRAF V600–positive high-grade glioma (HGG).. Journal of Clinical Oncology. 36(15_suppl). 10505–10505. 6 indexed citations
9.
García, Heathcliff Dorado, Ian C. MacArthur, Koshi Imami, et al.. (2018). Abstract 2628: Synthetic lethal targeting of ATR in alternative lengthening of telomeres-dependent rhabdomyosarcoma. Cancer Research. 78(13_Supplement). 2628–2628. 1 indexed citations
10.
Timme, Natalie, Shuai Liu, Heathcliff Dorado García, et al.. (2018). Abstract 2624: Dual PLK1 and BRD4 inhibition has synergistic therapeutic effects against high-risk rhabdomyosarcoma. Cancer Research. 78(13_Supplement). 2624–2624. 1 indexed citations
11.
Hargrave, Darren, Olaf Witt, Kenneth J. Cohen, et al.. (2018). Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600–mutant high-grade glioma (HGG) or low-grade glioma (LGG). Annals of Oncology. 29. viii132–viii132. 6 indexed citations
12.
Pita, Guillermo, Ana Patiño‐García, Purificación García‐Miguel, et al.. (2016). Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome. Annals of Oncology. 27(9). 1788–1793. 8 indexed citations
13.
Lissat, Andrej, Dheeraj Shinde, Till Braunschweig, et al.. (2015). IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells. BMC Cancer. 15(1). 552–552. 27 indexed citations
14.
Lissat, Andrej, et al.. (2012). Targeted Therapy in Ewing Sarcoma. SHILAP Revista de lepidopterología. 2012. 1–9. 3 indexed citations
15.
Winter, Georg, Uwe Rix, Andrej Lissat, et al.. (2011). An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B. Molecular Cancer Therapeutics. 10(10). 1846–1856. 32 indexed citations
16.
Lissat, Andrej, Thomas Vraetz, Maria Tsokos, et al.. (2007). Interferon-γ Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity. American Journal Of Pathology. 170(6). 1917–1930. 31 indexed citations
17.
Mendoza, Arnulfo, Ralf A. Hilger, Miriam Erlacher, et al.. (2007). Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma. Cancer Chemotherapy and Pharmacology. 62(1). 19–31. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. L. Woodward Breakdown of academic impact, for papers by Luca Paruzzo Breakdown of academic impact, for papers by Shyamprasad Deraje Vasudeva Breakdown of academic impact, for papers by L. Nolan Breakdown of academic impact, for papers by Manuel Torres-Diz Breakdown of academic impact, for papers by Fenglin Zang Breakdown of academic impact, for papers by J A P Spijkers-Hagelstein Breakdown of academic impact, for papers by Candace Shelton Breakdown of academic impact, for papers by Andrea Garofalo Breakdown of academic impact, for papers by Hengyu Lu
Rankless by CCL
2026